Geode Capital Management
EWTX icon

Geode Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Geode Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.3M Buy
2,174,051
+384,232
+21% +$13.2M ﹤0.01% 1291
2026
Q1 		$56.4M Buy
1,789,819
+43,597
+2% +$1.26M ﹤0.01% 1427
2025
Q4 		$43.3M Buy
1,746,222
+28,581
+2% +$574K ﹤0.01% 1576
2025
Q3 		$27.9M Sell
1,717,641
-79,574
-4% -$1.13M ﹤0.01% 1832
2025
Q2 		$23.6M Buy
1,797,215
+141,551
+9% +$2.04M ﹤0.01% 1875
2025
Q1 		$36.4M Buy
1,655,664
+55,093
+3% +$1.45M ﹤0.01% 1564
2024
Q4 		$42.7M Buy
1,600,571
+1,036
+0.1% +$33K ﹤0.01% 1525
2024
Q3 		$42.7M Sell
1,599,535
-73,118
-4% -$1.45M ﹤0.01% 1518
2024
Q2 		$30.1M Buy
1,672,653
+302,756
+22% +$5.28M ﹤0.01% 1696
2024
Q1 		$25M Buy
1,369,897
+422,851
+45% +$6.72M ﹤0.01% 1790
2023
Q4 		$10.4M Buy
947,046
+55,278
+6% +$388K ﹤0.01% 2325
2023
Q3 		$5.11M Buy
891,768
+35,556
+4% +$242K ﹤0.01% 2628
2023
Q2 		$6.64M Buy
856,212
+80,725
+10% +$681K ﹤0.01% 2542
2023
Q1 		$5.17M Buy
775,487
+53,342
+7% +$494K ﹤0.01% 2614
2022
Q4 		$6.46M Buy
722,145
+198,624
+38% +$1.86M ﹤0.01% 2514
2022
Q3 		$5.15M Buy
523,521
+126,691
+32% +$1.28M ﹤0.01% 2659
2022
Q2 		$3.16M Sell
396,830
-41,311
-9% -$312K ﹤0.01% 2949
2022
Q1 		$4.25M Buy
438,141
+46,559
+12% +$599K ﹤0.01% 2890
2021
Q4 		$5.98M Buy
391,582
+148,663
+61% +$2.67M ﹤0.01% 2795
2021
Q3 		$4.03M Buy
242,919
+497
+0.2% +$8.99K ﹤0.01% 3037
2021
Q2 		$5.17M Buy
+242,422
New +$6.63M ﹤0.01% 2880

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's EWTX Position: Q2 2026 in Review

Geode Capital Management increased its Edgewise Therapeutics (EWTX) stake by 21% in Q2 2026, buying an estimated $13.2M and bringing the position to 2,174,051 shares worth $88.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Geode Capital Management first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Geode Capital Management held 2,174,051 shares of Edgewise Therapeutics worth $88.3M as of Q2 2026.
  • Geode Capital Management bought 384,232 Edgewise Therapeutics shares in Q2 2026, an estimated $13.2M.
  • Edgewise Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1291 holding.
  • Geode Capital Management first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.